Neumora Therapeutics, Inc. NMRA
Updated: 10 Aug 2026
No signal published yet
We already track Neumora Therapeutics and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Neumora Therapeutics, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Neumora Therapeutics free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On June 15, 2026, Neumora announced that its Phase 3 KOASTAL-2 and KOASTAL-3 trials for lead candidate navacaprant in major depressive disorder failed to meet their primary endpoints, resulting in the program's discontinuation and a 35% workforce reduction. Subsequently, on July 27, 2026, the company reported favorable toxicology results for its NLRP3 inhibitor NMRA-215, supporting plans for clinical advancement.
What Firelda Watch includes for Neumora Therapeutics, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Neumora Therapeutics, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Neumora Therapeutics free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more